The week ahead...

Monday 22 September

NetDimensions, a provider of performance, knowledge and learning management systems to highly regulated industries, kicks off the week with interim results. It shares have drifted steadily lower since the beginning of the year despite a positive update in July. Then, it said first-half sales are up 49% to $9.1 million (£5.5 million) and invoiced sales from new business rose 79% to $3.4 million.

Analysts' expectations: Shareholders will be hoping for good news to reverse the negative share price trend. An indication as to how the second half as started will be crucial. Panmure Gordon expects full-year sales of $20 million and a pre-tax loss of $3.8 million.

"From a valuation perspective we encourage investors to look at the 1.8x EV/Sales and 0.6x PEG as illustrative that the growth is not reflected in the undemanding share price," said the broker.

Trading statements

Lighthouse Group, GVC Holdings, China Chaintek United, Moss Bros Group, Netdimensions, Finsbury Food Group, Gemfields, Allergy Therapeutics, Dairy Crest Group.

AGM/EGM

Provexis, Amiad Water Systems, Megafon, Braveheart Investment Group, Eurasia Drilling.

Tuesday 23 September

AIM-listed software company Netcall has already told the City its second half went well and that full-year results "will be comfortably in line with market expectations."

Analysts' expectations: Northland Capital is looking for earnings per share (EPS) of 2.5p and increase in net cash of £1.4 million to £11.4 million. "Core to the growth story (and current rating) is the uptake of its social media and PCI payment solutions and we will be looking for an update," it says.

Trading statements

Barr, Netscientific, Aa, KBC Advanced Technologies, Netcall, PZ Cussons, Nahl Group, Horizon Discovery Group, Cupid, Centralnic Group, GLI Finance, Dolphin Capital Investors, Faroe Petroleum, Regenersis, Close Brothers Group.

AGM/EGM

Sirius Minerals, WYG, Bank Audi Sal(audi-saradar Gp), Marwyn Management Partners.

Wednesday 24 September

Clinigen did well in August. Shares in the drugs company surged by a quarter, and at the end of the month it bought the global rights to the oncology support therapy, Ethyol from AstraZeneca. Ethyol treats dry mouth, a side-effect in patients undergoing post-operative radiation treatment for head and neck cancer, and generated revenue of $4.9 million in 2013.

Analysts' expectations: Investec Securities forecasts revenue of £126.2 million for the year to 30 June, driving pre-tax profit up by 13% to £25.1 million. "Whilst we think the shares are unlikely to recover to their early 2014 levels (675p), we think upside potential remains material and the downside risk is overdone," said the broker.

Trading statements

Outsourcery, Proxama, Instem, Judges Scientific, Personal Group Holdings, Origin Enterprises, Clinigen Group, United Utilities Group.

AGM/EGM

First Property Group, Accumuli, Mirada , Continental Coal.

Thursday 25 September

Trading statements

Synairgen, Toumaz Holdings, Incadea, Dji Holdings, Epwin Group, Havelock Europa.

AGM/EGM

Penna Consulting, Ryanair Holdings, Camco Clean Energym, AcenciA Debt Strategies, AdEPT Telecom, Coal of Africa.

Friday 26 September

Trading statements

Public Service Properties Investments, Produce Investments, Digital Globe Services, Asian Citrus Holdings.

AGM/EGM

Dji Holdings, Alent, Filtronic, Fortune Oil, Industrial Multi Property Trust.